Aurobindo Pharma · NSE: AUROPHARMA · BSE: 524804

Q2 FY24 results · Jul–Sep 2023

Aurobindo Pharma reported revenue from operations of ₹7,219.42 crore (up 25.8% from Q2 FY23) and net profit of ₹751.94 crore (up 83.2% from Q2 FY23) for Q2 FY24 (Jul–Sep 2023), on a consolidated basis.

Consolidated · ₹ crore
Item	Q2 FY24	Q2 FY23	YoY	Q1 FY24	QoQ
Revenue from operations	7,219.42	5,739.37	+25.8%	6,850.52	+5.4%
Other income	186.98	57.19	+226.9%	116.33	+60.7%
Total income	7,406.40	5,796.56	+27.8%	6,966.85	+6.3%
Profit before share of associates & JVs and tax	1,074.74	524.59	+104.9%	814.84	+31.9%
Share of profit/(loss) of associates & JVs	0.90	(1.23)		(2.81)
Net profit for the period	751.94	410.37	+83.2%	569.71	+32.0%
Attributable to shareholders of the company	757.18	409.45	+84.9%	570.75	+32.7%
EPS, basic (₹)	12.83	6.99	+83.5%	9.74	+31.7%
Net margin (%)	10.4	7.2		8.3

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q2 FY24	Q2 FY23	YoY	Q1 FY24	QoQ
Revenue from operations	2,668.76	3,025.66	−11.8%	2,390.82	+11.6%
Other income	67.08	55.86	+20.1%	94.88	−29.3%
Total income	2,735.84	3,081.52	−11.2%	2,485.70	+10.1%
Profit before tax	509.78	223.76	+127.8%	426.04	+19.7%
Net profit for the period	415.74	164.63	+152.5%	335.95	+23.8%
EPS, basic (₹)	7.10	2.81	+152.7%	5.74	+23.7%
Net margin (%)	15.6	5.4		14.1

Consolidated

Filed with BSE: 13 Nov 2023, 15:33 IST
Board meeting: 09 Nov 2023
Period: 01 Jul 2023 to 30 Sep 2023
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 13 Nov 2023, 15:33 IST
Board meeting: 09 Nov 2023
Period: 01 Jul 2023 to 30 Sep 2023
Review status: Unaudited
Source: XBRL filing on BSE